Becton Dickinson and Company (BDX) : Net money flow in Becton Dickinson and Company (BDX) was negative ($0.99 million) and the inflow of money on uptick was $0.31 million, whereas, the outflow of money on downticks amounted to $1.3 million on Thursday. The traders used every opportunity of price strength in the stock to sell their positions, hence, the total uptick to downtick ratio was 0.24. The block trades show that the large investors, were aggressive sellers in the stock. On the other hand, the total value of block trades done on downticks was $0 million. The money flow in block trades was negative ($0). Becton Dickinson and Company (BDX) gained $0.18 cent during the day and reached $172.25, a gain of 0.1% over the previous day.
Becton Dickinson and Company (BDX) : The most positive equity analysts on Becton Dickinson and Company (BDX) expects the shares to touch $190, whereas, the least positive believes that the stock will trade at $169 in the short term. The company is covered by 11 Wall Street Brokerage Firms. The average price target for shares are $180.64 with an expected fluctuation of $7.28 from the mean. The stock has recorded a 20-day Moving Average of 2.72% and the 50-Day Moving Average is 4.14%.
Becton Dickinson and Company (NYSE:BDX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $171.89 and $171.61 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $173.24. The buying momentum continued till the end and the stock did not give up its gains. It closed at $173.17, notching a gain of 0.64% for the day. The total traded volume was 859,443 . The stock had closed at $172.07 on the previous day.
Becton, Dickinson and Company is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Companys Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Companys BD Medical segment focuses on providing solutions to reduce the spread of infection, enhance diabetes treatment and advance drug delivery. The Companys BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers, clinical researchers, laboratory professionals and clinicians.